SOD1 and amyotrophic lateral sclerosis: ALS drug discovery is even more challenging due to the inherent difficulties in identifying compounds that bind to a mixture of transient aggregation species during aggregation, the fact that there are no natural ligands of SOD1 to serve as a molecular scaffold [71], and the heterogenous effects of mutations.